These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38567842)

  • 21. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
    Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologics for paediatric severe asthma: trick or TREAT?
    Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
    Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
    [No Abstract]   [Full Text] [Related]  

  • 24. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
    Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
    Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologics in allergic rhinitis.
    Bayar Muluk N; Cingi C
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of refractory asthma with antibodies].
    Lommatzsch M
    Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
    Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
    Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe asthma: When to resort to biological agents.
    Tenero L; Rossignoli S; Piacentini G
    Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologics for Asthma and Allergic Skin Diseases in Children.
    De Keyser HH; Chipps B; Dinakar C;
    Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34663682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life studies of biologics used in asthma patients: key differences and similarities to trials.
    Heffler E; Paoletti G; Giorgis V; Puggioni F; Racca F; Del Giacco S; Bagnasco D; Caruso C; Brussino L; Rolla G; Canonica GW
    Expert Rev Clin Immunol; 2019 Sep; 15(9):951-958. PubMed ID: 31389304
    [No Abstract]   [Full Text] [Related]  

  • 31. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insights from the trends of omalizumab and mepolizumab utilization in patients with asthma: A population-based cohort study using the National Database in Japan.
    Kan-O K; Noda T; Ogata H; Masaki K; Nishioka Y; Myojin T; Adachi T; Morita H; Imamura T; Tamari M; Kainuma K;
    Respir Investig; 2024 Jan; 62(1):113-120. PubMed ID: 38101278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential of biologics for the treatment of asthma.
    Pelaia G; Vatrella A; Maselli R
    Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of biologic therapy on airway hyperresponsiveness in asthma.
    Chan R; Lipworth B
    Ann Allergy Asthma Immunol; 2023 Jul; 131(1):37-41. PubMed ID: 36841374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Biologics for Atopic Diseases During Pregnancy.
    Shakuntulla F; Chiarella SE
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3149-3155. PubMed ID: 35987486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.
    Akenroye AT; Heyward J; Keet C; Alexander GC
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3969-3976. PubMed ID: 33556592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
    Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
    Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
    Nopsopon T; Lassiter G; Chen ML; Alexander GC; Keet C; Hong H; Akenroye A
    J Allergy Clin Immunol; 2023 Mar; 151(3):747-755. PubMed ID: 36538979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.